Ambrisentan - Wikipedia, the free encyclopedia
Ambrisentan (U.S. trade name Letairis; E.U. trade name Volibris) is a drug indicated for use in the treatment of pulmonary hypertension. It functions as an endothelin receptor ...
Endothelin receptor antagonist - Wikipedia, the free encyclopedia
A endothelin receptor antagonist (ERA) is a drug that blocks endothelin receptors. Two main kinds of ERAs exist: selective ERAs (sitaxentan, ambrisentan, atrasentan), which affect ...
Letairis (ambrisentan) Medication Guide
Medication Guide. LETAIRIS™ (le-TAIR-is) Tablets (ambrisentan) Read this Medication Guide before you start taking LETAIRIS ... Active ingredient: ambrisentan ...
ambrisentan - Health.com
Ambrisentan is available only under a special program ... Home >> Diseases & Conditions >> A-Z Health Library >> ambrisentan. Back to previous page ...
Ambrisentan
What is this medicine? AMBRISENTAN (am bri SEN tan) is used to treat pulmonary hypertension. This medicine may help make exercise and breathing easier.
Letairis (Ambrisentan Tablets) Drug Information: Uses, Side Effects ...
Learn about the prescription medication Letairis (Ambrisentan Tablets), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling.
Ambrisentan (Oral Route) - MayoClinic.com
Mayo Clinic offers award-winning medical and health information and tools for healthy living. ... Ambrisentan is used to treat the symptoms of pulmonary ...
Drug Information for Ambrisentan Oral - WebMD
Find medical information for Ambrisentan Oral including side effects, drug interactions, images and pictures, medication uses, warnings, user ratings and reviews.
Ambrisentan
Hospital Pharmacy 1145 FORMULARY DRUG REVIEWS Ambrisentan Dennis J. Cada, PharmD, FASHP, FASCP* (Editor), Terri Levien, PharmD, † and Danial E. Baker, PharmD, FASCP, FASHP ...
CIGNA - ambrisentan
This medication can cause birth defects. Do not use if you are pregnant. Tell your doctor right away if you miss a menstrual period during treatment with ambrisentan.
GlaxoSmithKline's Volibris (ambrisentan) Receives Authorisation From ...
GlaxoSmithKline (GSK) announced that the European Commission has issued marketing authorisation for Volibris® (ambrisentan) for the treatment of Pulmonary Arterial Hypertension ...
PAH - AMBRISENTAN
Ambrisentan is an ETA selective receptor antagonist being developed as an oral therapy for patients with pulmonary arterial hypertension. Ambrisentan is member of a class of ...
Newly Approved Drug Therapies (956) Letairis (ambrisentan), Gilead,
Organized by therapeutic area, this comprehensive listing of FDA-Approved Drugs by the Food and Drug Administration features facts on clinical trial results, side effects and other ...
